

Genetic Protection with *Portulaca oleracea*: Cytogenetic Analysis of Dose-Dependent Herbal Response to Mutagenic Damage

HALİT KIZİLET

halitkizilet@adu.edu.tr

Adnan Menderes University

Research Article

Keywords: Sister Chromatid Exchange (SCE), Micronucleus (MN), *Portulaca oleracea*, antigenotoxic effect, genotoxicity, ethanol extract, chloroform extract

Posted Date: June 23rd, 2026

DOI: <https://doi.org/10.21203/rs.3.rs-9131231/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Additional Declarations: No competing interests reported.

Running Title: *Purslane: Against human genetic damage*

Genetic Protection with *Portulaca oleracea*: Cytogenetic Analysis of Dose-Dependent Herbal Response to Mutagenic Damage

Halit Kızılet

Aydın Adnan Menderes University, Soke Vocational School of Health Services, Soke, Aydın,

Türkiye

ORCID: <https://orcid.org/0000-0002-7289-4635>

Corresponding author's e mail: halitkizilet@adu.edu.tr

Abstract:

Background: In this study, the antigenotoxic effects of ethanol (PO_{eth}) and chloroform (PO_{chl}) extracts of *Portulaca oleracea* (purslane) against DNA damage induced by common genotoxic agents, ethyl methane sulfonate (EMS), mitomycin-C (MMC) and N-nitroso-N-ethylurea (ENU) were evaluated. Genomic damage and cytotoxic effects were analyzed by Sister Chromatid Exchange (SCE) and Micronucleus (MN) tests applied to human peripheral lymphocytes.

Results: Statistically significant increases in SCE and MN frequencies were detected in groups treated with EMS, MMC and ENU (P<0.05). In contrast, no significant genotoxicity was observed in groups in which PO_{eth} and PO_{chl} extracts were applied alone. Importantly, the use of these extracts together with genotoxic agents provided dose-dependent significant decreases in damage markers. The most significant protective effect was observed at 4 ppm extract doses, and significant decreases were recorded in SCE and MN rates.

Conclusions: This effect is thought to be due to the capacity of antioxidant compounds such as flavonoids, betalains, and ascorbic acid contained in *P. oleracea* to neutralize reactive oxygen species and possibly support DNA repair mechanisms. The findings show that *P. oleracea* has the potential to protect genome integrity under genotoxic stress and contribute to the development of plant-based

27 protective strategies. The obtained findings are promising that dietary intake of purslane or its
28 pharmacological formulations can be used to prevent DNA damage in case of exposure to genotoxic
29 chemicals.

30

31 **Keywords:** Sister Chromatid Exchange (SCE), Micronucleus (MN), *Portulaca oleracea*,
32 antigenotoxic effect, genotoxicity, ethanol extract, chloroform extract.

33

34

35 **Background**

36 All organisms are constantly exposed to DNA damaging agents in natural living conditions. DNA
37 damage occurs by endogenous cellular metabolic processes such as hydrolysis, oxidation, alkylation,
38 and DNA base mismatches, or by exogenous sources such as ultraviolet, ionizing radiation, and
39 chemicals. Most cancers are caused by exposure to external chemicals. Damage caused by agents to
40 DNA in the cell is the beginning of the carcinogenesis process. DNA repair processes work non-stop
41 to repair damage. However, replication of damaged DNA may also occur prior to repair. This leads
42 to gene mutations and the formation of altered proteins. The complex process of carcinogenesis
43 includes many such events (1). Damaged DNA that is not repaired properly can lead to genomic
44 instability leading to tumorigenesis. To maintain genomic stability, mammalian cells have evolved
45 DNA repair mechanisms (2). DNA repair mechanisms eliminate or treat damage to ensure survival.
46 At this stage, disruption or dysregulation of DNA repair leads to genome instability. It destabilizes
47 cellular metabolic homeostasis (3).

48 Genetic toxicology is a branch of science that studies the damage caused to DNA by chemicals, drugs,
49 and environmental agents and the changes in genetic material. This field is critical for understanding
50 the mechanisms of mutations, chromosomal aberrations, and carcinogenic processes (4). Genetic
51 toxicity tests are widely used in the safety assessment of chemicals, drug development processes, and
52 monitoring industrial exposures to protect human health and ecosystems (5). A genotoxic agent (or

53 genetic toxicant) refers to a substance that causes heritable changes in the genetic markers of an
54 organism. These agents affect the gametes in the gonads and lead to a decrease in the number of
55 gametes or changes in genetic information. When gametes from two different sexes fuse, the resulting
56 zygote, if it survives, may be genetically different from its parents. Such permanent changes in
57 genotype are called "mutations" and the agents that cause them are called "mutagens". Mutations can
58 also occur in somatic cells, but they are not hereditary. However, such changes are particularly
59 important because they can contribute to carcinogenesis (6,7).

60 Commonly used positive controls in genotoxicity testing include ethyl methanesulfonate (EMS),
61 mitomycin-C (MMC), and N-Nitroso-N-ethylurea (ENU), which are known for their mutagenic
62 properties (8). These agents differ significantly in their genotoxicity mechanisms.

63 EMS is a mutagenic, teratogenic, and carcinogenic organic compound and an alkylating agent that
64 has been used to study mutagenesis for more than 50 years. It transfers ethyl groups to DNA bases,
65 causing point mutations via replication errors. Mismatching leads to transition mutations (e.g. GC →
66 AT) and frameshift mutations (9). EMS alkylates the phosphate groups in the DNA backbone, causing
67 chain breaks and apurinic regions (10). It produces alkyl adducts that disrupt base pairing by primarily
68 targeting guanine at positions O⁶ and N⁷ (11).

69 MMC, a bioreductive alkylating agent, forms DNA interstrand crosslinks (ICL's). These cross-links
70 block replication and transcription, leading to mutations or cell death. ICL's physically block
71 replication forks, causing collapse and double-strand breaks (12). MMC also contributes to oxidative
72 damage by generating reactive oxygen species (ROS) via redox cycling (13,14). Insoluble ICL's
73 trigger chromatid exchanges and ROS-mediated oxidative stress (12,15). Although MMC is a potent
74 anticancer drug, its mutagenic and carcinogenic properties pose a risk for secondary malignancies
75 (16).

76 ENU, a potent nitrosamine derivative, forms O⁶-ethylguanine in DNA, leading to G:C→A:T
77 transitions. It also induces other base substitutions (AT→GC, AT→CG, AT→TA, GC→CG,
78 GC→TA) (17). ENU exposure leads to high mutation frequencies, genetic instability, DNA strand

79 breaks, and oxidative damage (18,19). Its mutagenicity is associated with alkylation of oxygen or
80 nitrogen atoms in DNA bases (20,21).

81 Increasing concerns about genotoxic agents have stimulated research on natural compounds with
82 protective effects. Genotoxicity testing not only identifies harmful agents but also evaluates
83 antigenotoxic substances for therapeutic use. Historically, natural materials, especially plants, have
84 been an integral part of human health. Ancient practices such as herbal teas, poultices, and pastes
85 continue today to treat diseases and combat toxins. Linking traditional and modern medicine,
86 pharmacognosy focuses on deriving bioactive compounds from plants for drug development.
87 Phytotherapy or herbal medicine remains relevant in the treatment of ailments, including cancer,
88 despite advances in medical science. Approximately 25% of prescription drugs are of plant origin
89 (22) and there are 650 medicinal plant species in Türkiye's flora (23).

90 Plant extracts are increasingly investigated for their ability to reduce damage caused by genotoxic
91 agents. Particularly rare plant species contain compounds that suppress mutagenic and carcinogenic
92 effects (24). DNA damage and oxidative stress form the basis of pathologies such as cancer and aging
93 (25). Natural plant compounds show protective activity against genotoxicity caused by oxidative
94 stress (7,26,27). Fruits and vegetables rich in phytochemicals show antimicrobial, antioxidant,
95 kızılantimutagenic and anticarcinogenic properties (28–30).

96 *P. oleracea*, widely used, recognized as a medicinal plant and designated as a "global medicinal plant"
97 by the World Health Organization (31,32), is rich in antioxidants, anti-inflammatory agents and
98 anticancer compounds (27). Historically used for its therapeutic properties, purslane is also valued as
99 a traditional kitchen ingredient. It has the highest omega-3 fatty acid content among green leafy
100 vegetables (33,34) and contains vitamins (A, B1, B2, C, niacinamide, nicotinic acid, α -tocopherol, β -
101 carotene), minerals (magnesium, calcium, potassium, iron) and two betalain alkaloid pigments (red
102 betacyanins and yellow betaxanthins) that have been shown to have antioxidant and antimutagenic
103 effects (35).

104 This study evaluates the protective effects of ethanol (PO_{eth}) and chloroform (PO_{chl}) extracts of
105 *Portulaca oleracea* (purslane) against genotoxicity induced by EMS, MMC and ENU. In this context,
106 sister chromatid exchange (SCE) test and micronucleus (MN) test are two main methods to determine
107 genomic and oxidative damage in lymphocyte cells.

108 The SCE test analyzes the exchange of genetic material between non-homologous chromatids during
109 cell division. In this test, DNA replication is monitored by adding bromodeoxyuridine (BrdU) to cell
110 culture. SCE's, visualized by fluorescence or Giemsa staining techniques, are an indicator of exposure
111 to genotoxic agents, particularly DNA cross-linking agents or free radicals (36). High SCE frequency
112 indicates activation of DNA repair mechanisms, thus playing an important role in cancer research and
113 drug toxicity studies (37).

114 The micronucleus test detects small nuclei (micronuclei) formed by chromosome fragments or
115 complete chromosomes that have separated from the main nucleus during cell division. This test can
116 be performed in in vitro (cell culture) or in vivo (human lymphocytes) models (38). Using
117 cytokinesis-blocked cells, clastogenic (chromosome breakage) and aneugenic (chromosome loss)
118 effects can be assessed simultaneously. The micronucleus test has been standardized by OECD (No.
119 487) and ICH guidelines (39) and is used in a wide range of areas from the pharmaceutical industry
120 to environmental monitoring (40).

121 Both tests are complementary to each other in determining genotoxic risks. The SCE test targets
122 damage at the DNA level, while the MN test targets anomalies at the chromosomal level. These
123 methods are an indispensable part of toxicological risk assessments and guide strategies to protect
124 human and environmental health (41).

125

126 **Methods**

127

128 **Chemicals**

129 Mitomycin-C (MMC) (cat. No: M5353), Ethyl methanesulfonate (EMS) (M0880), N-Nitroso-N-
130 ethylurea (ENU) (Cas no. 759-73-9), methanol (CAS No:67-56-1), dimethyl sulfoxide (CAS
131 No:6768-5), 5-bromo-2-deoxyuridine (CAS No: 59-14-3), potassium chloride (CAS No: 7447-40-
132 7), giemsa (CAS No: 51811-82-6), bisbenzimidazole H 33342 (CAS No:23491-52-3), sodium citrate
133 (CAS No: 613204-3), sodium chloride (CAS No:7647-14-5), acetic acid (CAS No: 64-19-
134 7),chromosome medium (CAS No: F 5023), colchicine (CAS No: L 6221) and cytochalasin-B (CAS
135 No: 14930-96-2) were purchased from the Sigma-Aldrich Company.

136

137

138

139 **Preparation of the methanol extracts of *Portulaca oleracea* L.**

140 Purslane plant, which was determined to be used as an antigenotoxic agent in the experiments, was
141 collected from the vicinity of Hasancık village in Adıyaman province and from an altitude of 600-
142 900 meters. The area where the samples were collected is public land belonging to the Non-Timber
143 Forest Products and Services Department of the General Directorate of Forestry, Ministry of Forestry
144 and Water Affairs of the Republic of Turkey, and is not subject to any permit (CIRCULAR NO: 302
145 INVENTORY AND PLANNING OF NON-TIMBER FOREST PRODUCTS AND PRINCIPLES OF
146 PRODUCTION AND SALE). Taxonomic identification was conducted by Prof. Dr. Özkan Eren
147 (Aydın Adnan Menderes University, Faculty of Science, Department of Biology, Division of Botany).
148 A voucher specimen (AYDN 12317) was deposited in the Herbarium of Adnan Menderes University
149 (AYDN), Aydın, Türkiye. Ethanol and chloroform extract (PO_{eth}, PO_{chl}) were prepared with all of the
150 above-ground organs of the purslane plant, such as stem, leaves and flowers, which were collected in
151 its natural environment, during the flowering period and from lands far from agriculture (29). PO_{eth}
152 and PO_{chl} extract were dissolved with DMSO in the course of applications.

153

154 **Donors for peripheral blood assays**

155 All donors were determined according to Kızılet *et al.*, (7). This study complies with all provisions
156 of the Declaration of Helsinki. Informed consent was obtained from all participants in the study. It
157 was approved by the Aydın Adnan Menderes University Faculty of Medicine, Non-Interventional
158 Clinical Research Ethics Committee (DECISION:02 Protocol No: 2025/120).

159

160 **Sister chromatid exchange (SCE) assay**

161 To determine the genotoxic and antigenotoxic effects of EMS, MMC and ENU (1 ppm) and different
162 concentrations PO_{eth} and PO_{chl} (1, 2 and 4 ppm) by SCE, 1–2.5 mL of human peripheral blood was
163 added to 5 mL chromosome media. Different sets were prepared for each concentration and each
164 donor. 5–bromo–2–deoxyuridine (BrdU) was added to all experiment sets at a final concentration of
165 10⁻⁴M. All substances added to the tubes were sterilized to prevent contamination during the
166 experimental stage. The experimental sets were incubated for 72 hours at 37 °C in dark incubators.
167 At 70 hours of the experiment, colchicine was added to the medium at a final concentration of 0.5
168 µg/mL to stop the mitosis at the metaphase stage. At the end of the 72 hours incubation, the tubes
169 were centrifuged and removed the supernatants. Hypotonic solution (0.075 M KCl) was added onto
170 pellet and incubated for 30 minutes in dark incubator at 37 °C. At the end of the time, the supernatant
171 was removed after centrifugation. The remaining pellet was washed with a fixative consisting of a
172 methanol/acetic acid (3:1 v/v) mixture. This procedure was repeated three times. Peripheral blood
173 smears were then prepared from the remaining pellet and allowed to dry in the dark for 3 days. These
174 preparations were stained according to Czepulkowski and Rooney (42) fluorescence plus Giemsa
175 method. For this purpose, preparations were wetted with 0.5 µg/mL bisBenzimide (Hoechst 33342)
176 for 20 minutes. Wet preparations were incubated for 1 hour under 366 nm UV. The preparations were
177 then kept in a 2 X SSC (1:1 v/v 0.03 M sodium citrate/0.03 M sodium chloride) solution in a 65 °C
178 water bath for 1 hour. Finally, the preparations were stained with 5% giemsa. Preparations were
179 examined at 1000 X magnification and sister chromatid changes were recorded on chromosomes in
180 metaphases. In addition, the replication index (RI) was calculated to determine the effects on DNA

181 replication. For this calculation, 100 randomly selected metaphase plates were separated from the
182 first, second and third metaphase stages, counted, recorded and calculated.

183

184 **Micronucleus assays**

185 EMS, MMC and ENU (1 ppm) and different concentrations of PO_{eth} and PO_{chl} (1, 2 and 4 ppm) were
186 used to determine the MN ratio in human peripheral lymphocytes using the micronucleus test
187 developed by Fenech (38) and Kirsch-Volders *et al.*, (43) was modified and used (7). 0.25 ml of blood
188 sample taken from the donor was added to 5 ml of prepared medium (chromosome medium b). It was
189 immediately incubated at 37±1 ° C. At 24 hours, 1 ppm EMS, 1 ppm MMC, 1 ppm ENU and different
190 concentrations of extract (1, 2 and 4 ppm) were added to EMS+PO_{eta}, EMS+PO_{chl}, MMC+PO_{eta},
191 MMC +PO_{chl} and ENU+PO_{eta}, ENU+PO_{chl} tubes separately. In addition to these, distilled water and
192 1% dimethyl sulfoxide (DMSO) as a solvent were prepared as negative controls. At the 48th hour,
193 cytochalasin-B was added to each tube at a final concentration of 3 µg/mL to prevent cytokinesis. At
194 the 72nd hour, the tubes were centrifuged at 1000 rpm and the supernatant was discarded, and
195 hypotonic solution was added instead. The tubes, which were kept at 37±1°C for five minutes, were
196 centrifuged again and the pellet part was fixed with the fixation solution. After the last centrifugation
197 process, smear preparations were prepared from the remaining pellet and stained with the giemsa
198 staining technique. These preparations were examined under a light microscope at 10x100
199 magnification, and MN counting was performed in binucleate cells (BNH) according to the criteria
200 determined by Countryman and Heddle (44). In addition, in order to determine the cytotoxic effect
201 of each pesticide, a thousand cells were randomly counted and the nuclear division index (NDI) was
202 calculated according to the number of nuclei.

203

204 **Statistical methods**

205 The sample size to be used in the SCE and MN tests was determined to be consistent with similar
206 studies in the literature and to ensure statistical significance (27,45,46). The sample size for both tests

207 was calculated using the G*Power 3.1 statistical analysis program with a 95% confidence level ($\alpha =$
208 0.05) and 80% test power ($1-\beta = 0.80$) based on previously reported effect sizes.

209 For the SCE test, the method reported by Latt *et al.*, (47) and Perry and Wolff (36) was used; a total
210 of 100 metaphase plates, 25 from each donor, and a total of 400 metaphase plates will be analyzed
211 for replication index (RI) evaluations. This sample size is at a level that will provide statistical
212 significance in detecting a 20% increase (48).

213 For the MN test, the protocol suggested by Fenech (38) and used in human peripheral lymphocytes
214 was taken into account; 1000 binucleated cells will be evaluated in each application group. This
215 number of cells was considered sufficient to detect 30% changes in micronucleus frequency (38).

216 The determined sample size aimed to keep the coefficient of variation (%CV) of the tests low and to
217 measure biological effects reliably.

218 In the study, the effect size was calculated based on average differences and standard deviations (49–
219 51).

220 A total of 100 metaphase plates, 25 from each donor, were analyzed for the SCE test, and a total of
221 400 metaphase plates, 100 from each donor, were analyzed for the Replication Index (RI). This design
222 was structured to allow the determination of 15–25% differences in chromosomal rearrangements, in
223 accordance with the standards recommended by Latt *et al.*, (47) and Perry and Wolff (36).

224 For the MN test, 1000 binucleated cells were examined in each treatment group. This sample size
225 was considered sufficient to reliably detect 20–30% changes in micronucleus frequency, in
226 accordance with the minimum cell number criteria reported by Fenech (38) and Kirsch-Volders *et al.*,
227 (43).

228 SPSS (Statistical Package for Social Sciences) version 22.0 software (IBM Corp., Armonk, NY, USA)
229 was used for data analysis in this study. Categorical data of the groups were compared using the chi-
230 square test. Continuous variable data were tested for normality using the Shapiro-Wilks test and
231 homogeneous distribution was tested using the Levene test. Continuous variable data showing normal
232 distribution were compared using the independent sample t-test. Data showing non-normal

233 distribution were compared using the Mann-Whitney U test. P values less than 0.05 were considered
234 statistically significant.

235

236 Results

237

238 SCE findings for control and purslane extracts

239 For this purpose, two separate control groups were created. The negative control group was distilled
240 water and DMSO, which was the solvent of all application groups. The average SCE's for distilled
241 water and DMSO were 3.59 ± 0.05 , 3.69 ± 0.07 (Table 1), respectively, and the difference between them
242 was statistically insignificant ($P > 0.05$). For this reason, the application groups were compared with
243 DMSO. Only the data obtained from the application of purslane ethanol (PO_{eth}) and chloroform
244 (PO_{chl}) extracts were 3.78 ± 0.09 , 3.82 ± 0.05 , respectively (Figure a) ($P > 0.05$).

245

246 In addition, the replication index (RI) was calculated for each application. The calculated RI values
247 for distilled water, DMSO, PO_{eth} and PO_{chl} are 2.41 ± 0.04 , 2.25 ± 0.06 , 2.38 ± 0.06 and 2.36 ± 0.03 ,
248 respectively (Table 1). According to these results, the difference between the control groups for RI
249 values was found to be statistically insignificant ($P > 0.05$).

250

251 **Table 1. SCE, RI values and statistical analysis results of the control and purslane groups**

Application groups	1st donor	2nd donor	3rd donor	SCE/Cell (Average)	Min.-Max. SCE	M1	M2	M3	RI
Distilled water	3,64	3,55	3,57	$3,59 \pm 0,05$	1-11	45	87	168	$2,41 \pm 0,04$
DMSO (%1)	3,76	3,60	3,72	$3,69 \pm 0,07$	1-10	46	95	146	$2,25 \pm 0,07$
PO_{eth} (1ppm)	3,78	3,76	3,80	$3,78 \pm 0,09$	1-10	47	96	158	$2,38 \pm 0,06$
PO_{chl} (1ppm)	3,80	3,82	3,84	$3,82 \pm 0,05$	1-11	45	91	160	$2,36 \pm 0,03$

Min.=minimum, Max.=maximum, ^aSignificant at 0.05 level compared to DMSO, P=0.05




Figure a. SCE/Cell data of control groups

SCE findings of EMS, MMC and ENU

In the study, the average SCE's for 1 ppm EMS, 1 ppm MMC and 1 ppm ENU were 22.31 ± 0.03 , 27.18 ± 0.05 and 21.16 ± 0.04 , respectively (Figure b), and were found to be significant at the $P < 0.05$ level when compared with DMSO (Table 2). In all applications, the highest SCE's in metaphase plates that had undergone the second mitosis were 42, 45 and 40 SCE/Cell, respectively.

RI values were measured as 2.03 ± 0.07 , 2.01 ± 0.01 and 2.05 ± 0.03 for EMS, MMC and ENU, respectively (Table 2). According to the findings, EMS, MMC and ENU reduced replication. However, it is statistically insignificant ($P > 0.05$).

Table 2. SCE, RI values and statistical analysis results of EMS, MMC and ENU application groups

Application groups	1st donor	2nd donor	3rd donor	SCE/Cell (Average)	Min.-Max. SCE	M1	M2	M3	RI
Distilled water	3,64	3,55	3,57	3,59±0,05	1-11	45	87	168	2,41±0,04
DMSO (%1)	3,76	3,60	3,72	3,69±0,07	1-10	46	95	146	2,25±0,07
EMS (1ppm)	21,21	23,95	21,76	22,31±0,03 ^a	7-42	45	84	132	2,03±0,07
MMC (1ppm)	28,67	27,82	25,05	27,18±0,05 ^a	11-45	45	87	128	2,01±0,01
ENU (1ppm)	21,01	22,32	20,15	21,16±0,04 ^a	5-40	46	90	130	2,05±0,03
Min.=minimum, Max.=maximum, ^a Significant at 0.05 level compared to DMSO, P=0.05									




Figure b. SCE/Cell data of EMS, MMC and ENU application groups

SCE findings obtained as a result of PO_{eth} and PO_{chl} application against EMS

272 To observe the effects of EMS+PO_{eth} and EMS+PO_{chl} on SCE, 1 ppm EMS was applied to blood
 273 cultures at twice and four times the concentration (1:1/v:v, 1:2/v:2v, 1:4/v:4v). The obtained SCE
 274 frequencies and RI values are presented in Table 3.

275 The observed SCE/Cell ratios were 12.13±0.04, 14.16±0.07, 7.07±0.03, 7.11±0.03, 3.87±0.05 and
 276 3.88±0.01 for 1EMS+1PO_{eth}, 1EMS+1PO_{chl}, 1EMS+2PO_{eth}, 1EMS+2PO_{chl}, 1EMS+4PO_{eth} and
 277 1EMS+4PO_{chl}, respectively (Table 3). The decrease in SCE/Cell ratios was significant for
 278 antigenotoxicity (P<0.05) (Figure c).

279 For the antigenotoxicity study, RI was also calculated in the application groups. RI values for
 280 1EMS+1PO_{eth}, 1EMS+1PO_{chl}, 1EMS+2PO_{eth}, 1EMS+2PO_{chl}, 1EMS+4PO_{eth} and 1EMS+4PO_{chl} were
 281 2.55±0.01, 2.49±0.05, 2.50±0.04, 2.50±0.02, 2.54±0.01 and 2.56±0.03, respectively (Table 3).
 282 Although RI values increased compared to the DMSO control group, the results were statistically
 283 insignificant at P>0.05.


284

285 **Table 3. SCE, RI values and statistical analysis results of EMS, PO_{eth} and PO_{chl} application**
 286 **groups**

Application groups	1st donor	2nd donor	3rd donor	SCE/Cell (Average)	Min.-Max. SCE	M1	M2	M3	RI
Distilled water	3,64	3,55	3,57	3,59±0,05	1-11	45	87	168	2,41±0,04
DMSO (%1)	3,76	3,60	3,72	3,69±0,07	1-10	46	95	146	2,25±0,07
EMS (1ppm)	21,21	23,95	21,76	22,31±0,03 ^a	7-42	45	84	132	2,03±0,07
1EMS+1PO _{eth}	14,10	10,16	12,14	12,13±0,04 ^b	5-25	43	97	176	2,55±0,01
1EMS+1PO _{chl}	14,12	14,21	14,15	14,16±0,07 ^b	5-25	44	95	171	2,49±0,05
1EMS+2PO _{eth}	7,04	7,07	7,11	7,07±0,03 ^b	4-13	45	90	175	2,50±0,04
1EMS+2PO _{chl}	7,13	7,10	7,11	7,11±0,03 ^b	3-17	45	88	176	2,50±0,02
1EMS+4PO _{eth}	3,84	3,92	3,86	3,87±0,05 ^b	1-12	46	88	180	2,54±0,01

1EMS+4PO _{chl}	3,86	3,86	3,92	3,88±0,01 ^b	1-11	46	89	181	2,56±0,03
Min.=minimum, Max.=maximum, ^a =Significant at 0.05 level compared to DMSO, ^b =Significant at 0.05 level according to EMS, P=0,05									

287



288

289 **Figure c. SCE/Cell data of EMS, PO_{eth} and PO_{chl} application groups**

290 **SCE findings obtained as a result of PO_{eth} and PO_{chl} application against MMC**

291 To observe the effects of MMC+PO_{eth} and MMC+PO_{chl} on SCE, 1 ppm MMC was applied to blood
292 cultures at twice and four times the concentration (1:1/v:v, 1:2/v:2v, 1:4/v:4v). The obtained SCE
293 frequencies and RI values are presented in Table 4.

294 The observed SCE/Cell ratios were 10,92±0,06, 10,75±0,03, 5,32±0,03, 5,17±0,02, 3,57±0,02 and
295 3,54±0,04 for 1MMC+1PO_{eth}, 1MMC+1PO_{chl}, 1MMC+2PO_{eth}, 1MMC+2PO_{chl}, 1MMC+4PO_{eth} and
296 1MMC+4PO_{chl}, respectively (Table 4). The decrease in SCE/Cell ratios was significant for
297 antigenotoxicity (P<0.05) (Figure d).

298 For the antigenotoxicity study, RI was also calculated in the application groups. RI values for
299 1MMC+1PO_{eth}, 1MMC+1PO_{chl}, 1MMC+2PO_{eth}, 1MMC+2PO_{chl}, 1MMC+4PO_{eth} and 1MMC+4PO_{chl}
300 were 2,52±0,03, 2,49±0,07, 2,53±0,06, 2,54±0,01, 2,54±0,07 and 2,55±0,05, respectively (Table 4).


301 Although RI values increased compared to the DMSO control group, the results were statistically
302 insignificant at P>0.05.

303

304 **Table 4. SCE, RI values and statistical analysis results of MMC, PO_{eth} and PO_{chl} application**
305 **groups**

Application groups	1st donor	2nd donor	3rd donor	SCE/Cell (Average)	Min.-Max. SCE	M1	M2	M3	RI
Distilled water	3,64	3,55	3,57	3,59±0,05	1-11	45	87	168	2,41±0,04
DMSO (%1)	3,76	3,60	3,72	3,69±0,07	1-10	46	95	146	2,25±0,07
MMC (1ppm)	28,67	27,82	25,05	27,18±0,05 ^a	11-45	45	87	128	2,01±0,01
1MMC+1PO _{eth}	10,11	11,06	11,58	10,92±0,06 ^b	1-16	45	89	178	2,52±0,03
1MMC+1PO _{chl}	10,13	10,12	12,01	10,75±0,03 ^b	1-15	45	91	173	2,49±0,07
1MMC+2PO _{eth}	5,07	5,16	5,72	5,32±0,03 ^b	1-11	44	92	176	2,53±0,06
1MMC+2PO _{chl}	5,13	5,18	5,19	5,17±0,02 ^b	1-11	45	92	177	2,54±0,01
1MMC+4PO _{eth}	3,14	3,72	3,85	3,57±0,02 ^b	1-10	45	91	178	2,54±0,07
1MMC+4PO _{chl}	3,88	3,18	3,56	3,54±0,04 ^b	1-10	46	92	179	2,55±0,05
Min.=minimum, Max.=maximum, ^a =Significant at 0.05 level compared to DMSO, ^b =Significant at 0.05 level according to MMC, P=0,05									

306



307

308 **Figure d.** SCE/Cell data of MMC, PO_{eth} and PO_{chl} application groups

309 **SCE findings obtained as a result of PO_{eth} and PO_{chl} application against ENU**

310 To observe the effects of ENU+PO_{eth} and ENU+PO_{chl} on SCE, 1 ppm ENU was applied to blood
311 cultures at twice and four times the concentration (1:1/v:v, 1:2/v:2v, 1:4/v:4v). The obtained SCE
312 frequencies and RI values are presented in Table 5.

313 The observed SCE/Cell ratios were 11,25±0,05, 11,85±0,02, 5,32±0,03, 5,56±0,05, 3,80±0,07 and
314 3,69±0,05 for 1ENU+1PO_{eth}, 1ENU+1PO_{chl}, 1ENU+2PO_{eth}, 1ENU+2PO_{chl}, 1ENU+4PO_{eth} and
315 1ENU+4PO_{chl}, respectively (Table 5). The decrease in SCE/Cell ratios was significant for
316 antigenotoxicity (P<0.05) (Figure e).

317 For the antigenotoxicity study, RI was also calculated in the application groups. RI values for
318 1ENU+1PO_{eth}, 1ENU+1PO_{chl}, 1ENU+2PO_{eth}, 1ENU+2PO_{chl}, 1ENU+4PO_{eth} and 1ENU+4PO_{chl} were
319 2,51±0,03, 2,50±0,06, 2,49±0,01, 2,53±0,03, 2,53±0,03 and 2,54±0,05, respectively (Table 5).

320 Although RI values increased compared to the DMSO control group, the results were statistically
321 insignificant at P>0.05.

322

323 **Table 5. SCE, RI values and statistical analysis results of ENU, PO_{eth} and PO_{chl} application**
324 **groups**

Application groups	1st donor	2nd donor	3rd donor	SCE/Cell (Average)	Min.-Max. SCE	M1	M2	M3	RI
Distilled water	3,64	3,55	3,57	3,59±0,05	1-11	45	87	168	2,41±0,04
DMSO (%1)	3,76	3,60	3,72	3,69±0,07	1-10	46	95	146	2,25±0,07
ENU (1ppm)	21,01	22,32	20,15	21,16±0,04 ^a	5-40	46	90	130	2,05±0,03
1ENU+1PO _{eth}	11,11	11,26	11,37	11,25±0,05 ^b	1-17	45	89	177	2,51±0,03
1ENU+1PO _{chl}	13,10	11,13	11,31	11,85±0,02 ^b	1-16	44	90	175	2,50±0,06
1ENU+2PO _{eth}	5,46	5,57	5,65	5,32±0,03 ^b	1-11	45	90	174	2,49±0,01

1ENU+2PO _{chl}	5,13	5,18	5,19	5,56±0,05 ^b	1-11	45	91	177	2,53±0,03
1ENU+4PO _{eth}	3,76	3,80	3,83	3,80±0,07 ^b	1-10	45	91	177	2,53±0,03
1ENU+4PO _{chl}	3,76	3,60	3,72	3,69±0,05 ^b	1-10	45	91	178	2,54±0,05

Min.=minimum, Max.=maximum, ^a=Significant at 0.05 level compared to DMSO, ^b=Significant at 0.05 level according to ENU, P=0,05




Figure e. SCE/Cell data of MMC, PO_{eth} and PO_{chl} application groups

MN findings of control and purslane extracts


In this study, MN was used as the second genotoxicity test. MN percentage was found as 0.73±0.09 in distilled water, 0.80±0.10 in DMSO, 0.77±0.06 in 1 ppm PO_{eth} and 0.80±0.70 in 1 ppm PO_{chl} in control groups (Figure f). The difference between distilled water, 1% DMSO and purslane extracts (P>0.05) was not significant. For this reason, statistical comparison was made with DMSO, which was the solvent of all treatment groups.

NBI values for distilled water, DMSO, 1 ppm PO_{eth} and 1 ppm PO_{chl} were 1.51±0.06, 1.53±0.10, 1.55±0.03 and 1.51±0.09, respectively (Table 6) (P>0.05).

Table 6. MN and NBI values of control groups in human peripheral lymphocyte cells

Application Groups	Number of BNC Examined	1 MN	2 MN	3 MN	MN (%)	NDI
Distilled water	3000	22	-	-	0,73±0,09	1,51±0,06
DMSO (%1)	3000	24	-	-	0,80±0,10	1,53±0,10
PO _{eth} (1ppm)	3000	23	-	-	0,77±0,06	1,55±0,03
PO _{chl} (1ppm)	3000	24	-	-	0,80±0,70	1,51±0,09
P=0.05, BNC: binucleated cell, NDI: Nuclear Division Index						

338



339

340 **Figure f.** MN% and NDI data of control groups

341

342 **MN findings of EMS, MMC and ENU**

343 In the study, MN percentages for 1 ppm EMS, 1 ppm MMC and 1 ppm ENU were 4.90 ± 0.08 ,
344 5.37 ± 0.06 and 4.37 ± 0.03 , respectively, and were found to be significant at $P < 0.05$ level when
345 compared with DMSO (Table 7). In EMS, MMC and ENU applications, 1-, 2- and 3-member MN's
346 were observed, and the highest number was detected in MMC (122 MN).

347 NBI values calculated to determine the cytotoxic effect were 1.29 ± 0.07 , 1.20 ± 0.04 and 1.30 ± 0.06 for
 348 EMS, MMC and ENU application groups, respectively (Table 7). When compared with DMSO, it
 349 was found to be significant at $P < 0.05$ level (Figure g).


350

351 **Table 7. MN and NBI values created by EMS, MMC and ENU in human peripheral lymphocyte**
 352 **cells**

Application Groups	Number of BNC Examined	1 MN	2 MN	3 MN	MN (%)	NDI
Distilled water	3000	22	-	-	0.73 ± 0.09	1.51 ± 0.06
DMSO (%1)	3000	24	-	-	0.80 ± 0.10	1.53 ± 0.10
EMS (1ppm)	3000	92	14	9	4.90 ± 0.08^a	1.29 ± 0.07^a
MMC (1ppm)	3000	94	17	11	5.37 ± 0.06^a	1.20 ± 0.04^a
ENU (1ppm)	3000	90	10	7	4.37 ± 0.03^a	1.30 ± 0.06^a

P=0.05, BNC: binucleated cell, NDI: Nuclear Division Index, ^a=Significant at the 0.05 level compared to DMSO.

353



354

355 **Figure g. %MN and NDI data of EMS, MMC and ENU**

356

357 **MN findings obtained as a result of PO_{eth} and PO_{chl} application against EMS**

358 To observe the effects of EMS+PO_{eth} and EMS+PO_{chl} on MN, 1 ppm EMS was applied to blood
359 cultures at two times and four times the concentrations (1:1/v:v, 1:2/v:2v, 1:4/v:4v). The obtained MN
360 percentages and NBI values are presented in Table 8.

361 The observed MN percentages were 2.27±0.05, 2.10±0.07, 1.80±0.07, 1.80±0.08, 1.10±0.01 and
362 1.07±0.06 for 1EMS+1PO_{eth}, 1EMS+1PO_{chl}, 1EMS+2PO_{eth}, 1EMS+2PO_{chl}, 1EMS+4PO_{eth} and
363 1EMS+4PO_{chl}, respectively (Figure h). The decrease in MN percentages was significant for
364 antigenotoxicity (P<0.05).

365 For the antigenotoxicity study, NBI was also calculated in the application groups. NBI values for
366 1EMS+1PO_{eth}, 1EMS+1PO_{chl}, 1EMS+2PO_{eth}, 1EMS+2PO_{chl}, 1EMS+4PO_{eth} and 1EMS+4PO_{chl}
367 were 1.44±0.05, 1.43±0.03, 1.48±0.04, 1.49±0.07, 1.50±0.07 and 1.50±0.08, respectively (Table 8).
368 NBI values approached the control group, DMSO. This improvement in cytotoxic effect was
369 statistically significant (P<0.05).

370

371 **Table 8. MN and NBI values created by EMS, PO_{eth} and PO_{chl} in human peripheral lymphocyte**
372 **cells**

Application Groups	Number of BNC Examined	1 MN	2 MN	3 MN	MN (%)	NDI
Distilled water	3000	22	-	-	0,73±0,09	1,51±0,06
DMSO (%1)	3000	24	-	-	0,80±0,10	1,53±0,10
EMS (1ppm)	3000	92	14	9	4,90±0,08 ^a	1,29±0,07 ^a
1EMS+1PO _{eth}	3000	66	1	-	2,27±0,05 ^b	1,44±0,05 ^b
1EMS+1PO _{chl}	3000	63	-	-	2,10±0,07 ^b	1,43±0,03 ^b
1EMS+2PO _{eth}	3000	54	-	-	1,80±0,07 ^b	1,48±0,04 ^b

1EMS+2PO _{chl}	3000	54	-	-	1,80±0,08 ^b	1,49±0,07 ^b
1EMS+4PO _{eth}	3000	33	-	-	1,10±0,01 ^b	1,50±0,07 ^b
1EMS+4PO _{chl}	3000	32	-	-	1,07±0,06 ^b	1,50±0,08 ^b

P=0.05, BNC: binucleated cell, NDI: Nuclear Division Index, ^a=Significant at the 0.05 level compared to DMSO, ^b=Significant at the 0.05 level compared to EMS.




Figure h. %MN and NDI data of PO_{eth} and PO_{chl} against EMS

MN findings obtained as a result of PO_{eth} and PO_{chl} application against MMC

To observe the effects of MMC+PO_{eth} and MMC+PO_{chl} on MN, 1 ppm MMC was applied to blood cultures at two times and four times the concentrations (1:1/v:v, 1:2/v:2v, 1:4/v:4v). The obtained MN percentages and NBI values are presented in Table 9.

The observed MN percentages were 2,47±0,01, 2,37±0,07, 1,83±0,05, 1,80±0,05, 1,20±0,02 and 1,10±0,05 for 1MMC+1PO_{eth}, 1MMC+1PO_{chl}, 1MMC+2PO_{eth}, 1MMC+2PO_{chl}, 1MMC+4PO_{eth} and 1MMC+4PO_{chl}, respectively (Figure i). The decrease in MN percentages was significant for antigenotoxicity (P<0.05).

For the antigenotoxicity study, NBI was also calculated in the application groups. NBI values for 1MMC+1PO_{eth}, 1MMC+1PO_{chl}, 1MMC+2PO_{eth}, 1MMC+2PO_{chl}, 1MMC+4PO_{eth} and

386 1MMC+4PO_{chl} were 1,40±0,02, 1,41±0,03, 1,47±0,05, 1,49±0,06, 1,49±0,05 and 1,50±0,02,
 387 respectively (Table 9). NBI values approached the control group, DMSO. This improvement in
 388 cytotoxic effect was statistically significant (P<0.05).

389

390 **Table 9. MN and NBI values created by MMC, PO_{eth} and PO_{chl} in human peripheral lymphocyte**
 391 **cells**

Application Groups	Number of BNC Examined	1 MN	2 MN	3 MN	MN (%)	NDI
Distilled water	3000	22	-	-	0,73±0,09	1,51±0,06
DMSO (%1)	3000	24	-	-	0,80±0,10	1,53±0,10
MMC (1ppm)	3000	94	17	11	5,37±0,06 ^a	1,20±0,04 ^a
1MMC+1PO _{eth}	3000	70	2	-	2,47±0,01 ^b	1,40±0,02 ^b
1MMC+1PO _{chl}	3000	69	1	-	2,37±0,07 ^b	1,41±0,03 ^b
1MMC+2PO _{eth}	3000	55	-	-	1,83±0,05 ^b	1,47±0,05 ^b
1MMC+2PO _{chl}	3000	54	-	-	1,80±0,05 ^b	1,49±0,06 ^b
1MMC+4PO _{eth}	3000	36	-	-	1,20±0,02 ^b	1,49±0,05 ^b
1MMC+4PO _{chl}	3000	33	-	-	1,10±0,05 ^b	1,50±0,02 ^b
P=0.05, BNC: binucleated cell, NDI: Nuclear Division Index, ^a =Significant at the 0.05 level compared to DMSO, ^b =Significant at the 0.05 level compared to MMC.						

392




Figure i. %MN and NDI data of PO_{eth} and PO_{chl} against MMC

MN findings obtained as a result of PO_{eth} and PO_{chl} application against ENU

To observe the effects of ENU+PO_{eth} and ENU+PO_{chl} on MN, 1 ppm ENU was applied to blood cultures at two times and four times the concentrations (1:1/v:v, 1:2/v:2v, 1:4/v:4v). The obtained MN percentages and NBI values are presented in Table 10.


The observed MN percentages were $2,17 \pm 0,06$, $2,17 \pm 0,05$, $1,73 \pm 0,04$, $1,70 \pm 0,07$, $1,10 \pm 0,06$ and $1,03 \pm 0,03$ for 1ENU+1PO_{eth}, 1ENU+1PO_{chl}, 1ENU+2PO_{eth}, 1ENU+2PO_{chl}, 1ENU+4PO_{eth} ve 1ENU+4PO_{chl}, respectively (Figure j). The decrease in MN percentages was significant for antigenotoxicity ($P < 0.05$).

For the antigenotoxicity study, NBI was also calculated in the application groups. NBI values for 1ENU+1PO_{eth}, 1ENU+1PO_{chl}, 1ENU+2PO_{eth}, 1ENU+2PO_{chl}, 1ENU+4PO_{eth} ve 1ENU+4PO_{chl} were $1,43 \pm 0,07$, $1,43 \pm 0,08$, $1,45 \pm 0,04$, $1,45 \pm 0,05$, $1,49 \pm 0,04$ and $1,50 \pm 0,03$, respectively (Table 10). NBI values approached the control group, DMSO. This improvement in cytotoxic effect was statistically significant ($P < 0.05$).

Table 9. MN and NBI values created by ENU, PO_{eth} and PO_{chl} in human peripheral lymphocyte cells

Application Groups	Number of BNC Examined	1 MN	2 MN	3 MN	MN (%)	NDI
Distilled water	3000	22	-	-	0,73±0,09	1,51±0,06
DMSO (%1)	3000	24	-	-	0,80±0,10	1,53±0,10
ENU (1ppm)	3000	90	10	7	4,37±0,03 ^a	1,30±0,06 ^a
1ENU+1PO _{eth}	3000	65	-	-	2,17±0,06 ^b	1,43±0,07 ^b
1ENU+1PO _{chl}	3000	65	-	-	2,17±0,05 ^b	1,43±0,08 ^b
1ENU+2PO _{eth}	3000	52	-	-	1,73±0,04 ^b	1,45±0,04 ^b
1ENU+2PO _{chl}	3000	51	-	-	1,70±0,07 ^b	1,45±0,05 ^b
1ENU+4PO _{eth}	3000	33	-	-	1,10±0,06 ^b	1,49±0,04 ^b
1ENU+4PO _{chl}	3000	31	-	-	1,03±0,03 ^b	1,50±0,03 ^b
P=0.05, BNC: binucleated cell, NDI: Nuclear Division Index, ^a =Significant at the 0.05 level compared to DMSO, ^b =Significant at the 0.05 level compared to ENU.						

411



412

413 **Figure j.** %MN and NDI data of PO_{eth} and PO_{chl} against ENU

414

415 **Discussion**

416 Genotoxic chemicals are substances that can cause permanent changes in genetic material by directly
417 or indirectly damaging DNA. Among these chemicals, Ethyl Methane Sulfonate (EMS), Mitomycin-
418 C (MMC) and N-Nitroso-N-ethylurea (ENU) are widely used in research and are well-known agents.
419 Each of them causes genotoxicity with different mutation mechanisms. In this study, the antigenotoxic
420 effects of ethanol (PO_{eta}) and chloroform (PO_{chl}) extracts of *Portulaca oleracea* (purslane) against
421 genotoxic agents such as EMS, MMC and ENU were evaluated in human peripheral lymphocyte cells
422 using the Sister Chromatid Exchange (SCE) Test and the Micronucleus (MN) Test. While there was
423 no statistically significant difference ($P>0.05$) between the negative control groups (distilled water,
424 DMSO, PO_{eta} and PO_{chl}), the difference in genotoxic (average SCE and %MN) and cytotoxic
425 (Replication Index and Nuclear Division Index) values of the positive controls (EMS, MMC, ENU)
426 was statistically significant ($P<0.05$).

427 The genotoxic effects of EMS, MMC and ENU occur through different mechanisms. While EMS and
428 ENU cause mutations by adding alkyl groups to DNA bases, MMC mostly causes genomic instability
429 by forming cross-links in DNA. Studies on the genotoxic effects of these chemicals are important,
430 especially in terms of understanding carcinogenicity, mutagenicity and genetic diseases. While
431 alkylating agents such as EMS and ENU cause mutations by covalently binding to DNA bases, MMC
432 forms DNA cross-links. EMS and ENU usually cause point mutations. ENU and EMS are ethylating
433 agents, but their chemical properties are different. EMS has a high Swain-Scott substrate constant (S)
434 and reacts predominantly with ring nitrogen atoms in DNA (high nucleophilicity), while ENU, which
435 has a lower S value, reacts significantly with oxygen atoms. Alkylated oxygen atoms, especially O⁶-
436 alkylguanine, play an important role in the induction of gene mutations. O⁶-alkylguanine can pair
437 with thymine to lead to GC to AT transitions (52–54). EMS causes incorrect base pairing by adding
438 ethyl groups to guanine and thymine bases in DNA. O⁶-ethylguanine bases formed as a result of
439 ethylation are incorrectly paired during replication and cause G:C→A:T transition mutations. The
440 mutation mechanism of EMS is particularly prone to creating transition mutations (55). Recent
441 studies have shown that EMS has potential adverse effects such as cancer, birth anomalies and

hereditary effects (56–58). ENU, on the other hand, ethylates DNA bases by adding ethyl groups, especially at the O² and O⁴ positions of adenine. This leads to A:T → T:A and G:C → A:T transition mutations (59–61). ENU, high mutation frequencies and genetic instability are observed in its applications. It also causes DNA strand breaks and oxidative damage (19). The toxicity of these agents is also associated with the excessive production of reactive oxygen species (ROS). It shows its mutagenic activity by affecting oxygen or nitrogen atoms in DNA bases (62). MMC, on the other hand, causes replication fork collapse and double-strand breaks by forming interstrand cross-links that physically block replication and transcription (12). These cross-links can inhibit DNA replication and transcription and disrupt genomic stability. MMC can particularly trigger double-strand breaks and chromosomal aberrations. The genotoxic effects of MMC are cell cycle dependent and are mostly more effective in G1 and S phases (63). In addition, it causes oxidative damage by producing reactive oxygen species (ROS) through the redox cycle (13,14). It is also known to cause oxidative damage in the cell by cross-linking with DNA and adding an alkyl group (64). It also produces interstrand cross-links (ICL's) that stop replication forks. Insoluble ICL's cause chromatid exchanges and ROS-mediated oxidative damage (12,14,15). MMC is often used as a powerful anticancer agent in cancer treatment and has mutagenic and carcinogenic properties that cause secondary cancer (16). Studies in endothelial cells show that genotoxic stress caused by MMC causes cell cycle arrest and cell death (65).

The effects of genotoxic agents (EMS, MMC and ENU) used in the study on DNA are consistent with the literature. Statistically significant increases were observed in the frequencies of SCE and MN in the groups where EMS, MMC and ENU were applied alone ($P < 0.05$). For example, the average SCE values in the group applied EMS, MMC and ENU were measured as 22.31 ± 0.03 , 27.18 ± 0.05 and 21.16 ± 0.04 , respectively, which revealed a significant genotoxic effect compared to the control group (DMSO: 3.69 ± 0.07). Similarly, MN percentages were also significantly increased by genotoxic agents (DMSO: $0.80 \pm 0.10\%$, EMS: $4.90 \pm 0.08\%$; MMC: $5.37 \pm 0.06\%$; ENU: $4.37 \pm 0.03\%$). These findings confirm the damage mechanisms of these agents on DNA and chromosomes.

468 In the groups where PO_{eth} and PO_{chl} extracts were applied alone, no statistically significant difference
469 was found in the values of SCE and MN compared to the control groups (distilled water and DMSO)
470 ($P>0.05$). These results show that purslane extracts do not have direct genotoxic and cytotoxic effects.
471 This finding is consistent with the studies in the literature that purslane is rich in antioxidant
472 components (flavonoids, omega-3 fatty acids, ascorbic acid) and does not cause DNA damage
473 (66,67).

474 Therefore, when purslane extracts were applied together with genotoxic agents, a significant decrease
475 in the frequencies of SCE and MN was observed in a dose-dependent manner. For example, PO_{eth}
476 applied together with EMS decreased the SCE value from 22.31 ± 0.03 to 3.87 ± 0.05 . Similarly, the
477 percentages of MN were also significantly reduced (EMS+4PO_{eth}: $1.10\pm0.01\%$; EMS+4PO_{chl}:
478 $1.07\pm0.06\%$). This effect can be explained by the antioxidant and DNA repair mechanism activating
479 properties of purslane extracts. Flavonoids and phenolic compounds contained in purslane can reduce
480 oxidative stress by neutralizing free radicals (7,68,69).

481 The antigenotoxic effects of *Portulaca oleracea* against EMS, MMC and ENU may be associated with
482 its high antioxidant capacity. Purslane is rich in components such as flavonoids, betalains and ascorbic
483 acid, which can reduce oxidative stress by neutralizing free radicals (70). The reduction of mutations
484 caused by these genotoxic agents by purslane extracts can probably be explained by their ability to
485 scavenge reactive oxygen species (ROS) or activate DNA repair mechanisms. Components such as
486 ascorbic acid and α -tocopherol can prevent DNA damage by neutralizing ROS (71). In particular,
487 betalains have been shown to prevent the formation of DNA adducts induced by alkylating agents in
488 experimental models. Similarly, Oliveira et al. (72) attributed the hepatoprotective effect of *Portulaca*
489 *oleracea* to its antioxidant activity. In this study, the decrease in the effect with increasing doses of
490 extracts may be associated with the emergence of pro-oxidant effects at high concentrations. This is
491 consistent with the literature on the paradoxical behavior of antioxidants (73). The decrease in mean
492 SCE, SCE/cell and %MN values in PO_{eth} and PO_{chl} groups indicates that the antigenotoxic effect
493 becomes more pronounced as the extract concentration increases. The differences in the efficacy of

PO_{eth} and PO_{chl} extracts may be related to the polarity of the extraction solvents. While ethanol better captures polar compounds (flavonoids, phenolic acids), chloroform captures lipophilic compounds (terpenoids, fatty acids) (74). In this study, the strong antigenotoxic effect of purslane against EMS and ENU can be explained by the superiority of flavonoids in reducing alkylation damage. In contrast, its effectiveness against MMC can be associated with the ability of terpenoids to inhibit DNA cross-linking (12,75–77). It has been reported that *Portulaca oleracea* extracts increase the expression of enzymes such as glutathione-S-transferase (GST) and superoxide dismutase (SOD) by stimulating the Nrf2/ARE pathway (78,79). These enzymes play a critical role in the detoxification of electrophilic carcinogens such as EMS and ENU. Therefore, the reduction of genotoxicity by the extracts can be explained not only by the antioxidant effect but also by the modulation of cellular defense mechanisms. These findings emphasize that the chemical diversity of plant extracts is decisive in pharmacological effects. For example, Ethanol and acetone extracts of *Portulaca oleracea* showed strong DPPH, ABTS and hydroxyl radical scavenging activities while chloroform and n-hexane extracts showed significant superoxide radical scavenging activity (80).

In the study, the antigenotoxic effect became more pronounced as the extract concentration increased, supporting the dose-response relationship. However, the plateauing or slight decrease in the effect at high doses may indicate the pro-oxidant behavior of antioxidants. This paradox is explained by the interaction of antioxidants with metal ions and the production of ROS, especially at high concentrations (81). Similarly, there are studies in which *Portulaca oleracea* extracts reacted with Fe²⁺ ions and produced hydroxyl radicals (82). This situation reveals the importance of determining the optimal dose range of extracts.

515

516 **Conclusions**

517

518 This study confirms the antigenotoxic and anticytotoxic effects of *Portulaca oleracea* extracts against
519 genotoxic and cytotoxic agents. Especially the dose-response relationship and the diversity of

520 components support the use of this plant as a protective agent. It was revealed that ethanol and
521 chloroform extracts of *Portulaca oleracea* significantly reduced the toxicity caused by EMS, MMC
522 and ENU. The effect became more pronounced especially with the increase in dose, emphasizing the
523 protective potential of these extracts. The obtained findings are promising that dietary intake of
524 purslane or its pharmacological formulations can be used to prevent DNA damage in case of exposure
525 to genotoxic chemicals.

526

527 **Declarations**

528 ***Ethics approval and consent to participate:*** This study complies with all provisions of the
529 Declaration of Helsinki. Informed consent was obtained from all participants in the study. It was
530 approved by the Aydın Adnan Menderes University Faculty of Medicine, Non-Interventional Clinical
531 Research Ethics Committee (DECISION:02 Protocol No: 2025/120).

532 The area where the *Portulaca oleracea* samples were collected is public land belonging to the Non-
533 Timber Forest Products and Services Department of the General Directorate of Forestry, Ministry of
534 Forestry and Water Affairs of the Republic of Turkey, and is not subject to any permit (CIRCULAR
535 NO: 302 INVENTORY AND PLANNING OF NON-TIMBER FOREST PRODUCTS AND
536 PRINCIPLES OF PRODUCTION AND SALE). A sample of this material is not kept in a publicly
537 accessible herbarium.

538 ***Consent for publication:*** All of the material is owned by the authors and/or no permissions are
539 required.

540 ***Availability of data and materials:*** The data that support the findings of this study are available from
541 the corresponding author, [HK], upon reasonable request.

542 ***Competing interests:*** I declare that the authors have no competing interests as defined by BMC, or
543 other interests that might be perceived to influence the results and/or discussion reported in this paper.

544 ***Funding:*** This research did not receive funding.

545 ***Authors' contributions:*** All stages of the study were carried out by the author.

546 **Acknowledgements:** I would like to thank Prof. Dr. Özkan Eren (Aydın Adnan Menderes University,
547 Faculty of Science, Department of Biology, Division of Botany) for her valuable contributions
548 identification of the plant material.

549

550 **References**

- 551 1. Basu AK, Nohmi T. Chemically-induced DNA damage, mutagenesis, and cancer. Vol. 19,
552 International Journal of Molecular Sciences. MDPI; 2018. p. 1767.
- 553 2. Jia P, Her C, Chai W. DNA excision repair at telomeres. DNA Repair (Amst). 2015;36:137–
554 45.
- 555 3. Chatterjee N, Walker GC. Mechanisms of DNA damage, repair, and mutagenesis. Environ Mol
556 Mutagen. 2017;58(5):235–63.
- 557 4. Dearfield KL, Gollapudi BB, Bemis JC, Benz RD, Douglas GR, Elespuru RK, et al. Next
558 generation testing strategy for assessment of genomic damage: A conceptual framework and
559 considerations. Environ Mol Mutagen. 2017;58(5):264–83.
- 560 5. Kirkland D, Kasper P, Martus HJ, Müller L, van Benthem J, Madia F, et al. Updated
561 recommended lists of genotoxic and non-genotoxic chemicals for assessment of the
562 performance of new or improved genotoxicity tests. Mutation Research/Genetic Toxicology
563 and Environmental Mutagenesis. 2016 Jan 1;795:7–30.
- 564 6. Vural NT. Ankara Üniversitesi Eczacılık Fakültesi Yayınları. Baskı Ankara: Ankara
565 Üniversitesi Eczacılık Fakültesi Yayınları. 2005;
- 566 7. Kızılet H, Yilmaz B, Uysal H. Herbal medicine against genotoxicity of dimethoate, an
567 insecticide, in mammalian somatic cells. Heliyon. 2019;5(3).
- 568 8. Turkez H, Geyikoglu F, Mokhtar YI, Togar B. Eicosapentaenoic acid protects against 2, 3, 7,
569 8-tetrachlorodibenzo-p-dioxin-induced hepatic toxicity in cultured rat hepatocytes.
570 Cytotechnology. 2012;64:15–25.

- 571 9. Beranek DT. Distribution of methyl and ethyl adducts following alkylation with
572 monofunctional alkylating agents. *Mutation Research/Fundamental and Molecular*
573 *Mechanisms of Mutagenesis*. 1990;231(1):11–30.
- 574 10. Ohta T, Watanabe-Akanuma M, Yamagata H. A comparison of mutation spectra detected by
575 the *Escherichia coli* Lac⁺ reversion assay and the *Salmonella typhimurium* His⁺ reversion
576 assay. *Mutagenesis*. 2000;15(4):317–23.
- 577 11. Sega GA. A review of the genetic effects of ethyl methanesulfonate. *Mutation*
578 *Research/Reviews in Genetic Toxicology*. 1984;134(2–3):113–42.
- 579 12. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. *Nat Rev Cancer*.
580 2011;11(7):467–80.
- 581 13. Kryston TB, Georgiev AB, Pissis P, Georgakilas AG. Role of oxidative stress and DNA damage
582 in human carcinogenesis. *Mutation Research/Fundamental and Molecular Mechanisms of*
583 *Mutagenesis*. 2011;711(1–2):193–201.
- 584 14. Alpsoy L, Orhan F, Nardemir G, Agar G, Gulluce M, Aslan A. Antigenotoxic potencies of a
585 lichen species, *Evernia prunastri*. *Toxicol Ind Health*. 2015;31(2):153–61.
- 586 15. Tomasz M, Palom Y. The mitomycin bio-reductive antitumor agents: Cross-linking and
587 alkylation of DNA as the molecular basis of their activity. *Pharmacol Ther*. 1997 Oct 1;76(1–
588 3):73–87.
- 589 16. Niikawa M, Shin S, Nagase H. Suppressive effect of post-or pre-treatment of aspirin metabolite
590 on mitomycin C-induced genotoxicity using the somatic mutation and recombination test in
591 *Drosophila melanogaster*. *Biomedicine & pharmacotherapy*. 2007;61(2–3):113–9.
- 592 17. Shibuya T, Morimoto K. A review of the genotoxicity of 1-ethyl-1-nitrosourea. *Mutation*
593 *Research/Reviews in Genetic Toxicology*. 1993;297(1):3–38.
- 594 18. Lee WR, Beranek DT, Byrne BJ, Tucker AB. Comparison of dose-response relationships for
595 ethyl methanesulfonate and 1-ethyl-1-nitrosourea in *Drosophila melanogaster* spermatozoa.

- 596 Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis.
597 1990;231(1):31–45.
- 598 19. De Flora S, Bennicelli C, Serra D, Izzotti A, Cesarone CF. Role of glutathione and N-
599 acetylcysteine as inhibitors of mutagenesis and carcinogenesis. In: Absorption and utilization
600 of amino acids. CRC Press; 2018. p. 19–53.
- 601 20. Bignami M, Aquilina G, Zijno A, Frosina G, Abbondandolo A, Dogliotti E. DNA Repair of
602 Alkylation Damage and Its Relevance to Mutation Fixation in Mammalian Cells. DNA
603 Damage and Repair. 1989;87–95.
- 604 21. Guliaev AB, Singer B. DNA Damage: Alkylation. Encyclopedia of Biological Chemistry.
605 2004;609–13.
- 606 22. Rates SMK. Plants as source of drugs. Toxicon. 2001;39(5):603–13.
- 607 23. Baytop T. Türkiye’de Bitkiler ile Tedavi, İstanbul Üniv. Eczacılık Fak Yayınları. 1984;
- 608 24. Sanjib Bhattacharya SB. Natural antimutagens: a review. 2011;
- 609 25. Soltani F, Mosaffa F, Iranshahi M, Karimi G, Malekaneh M, Haghighi F, et al. Evaluation of
610 antigenotoxicity effects of umbelliprenin on human peripheral lymphocytes exposed to
611 oxidative stress. Cell Biol Toxicol. 2009;25:291–6.
- 612 26. Plazar J, Filipič M, Groothuis GMM. Antigenotoxic effect of Xanthohumol in rat liver slices.
613 Toxicology in vitro. 2008;22(2):318–27.
- 614 27. Kızılet H, Uysal H. Genoprotective role of purslane methanol extract against somatic
615 mutations induced by bifenthrin, a third generation prethyroid insecticide. J Agric Sci
616 (Belihuloya). 2022;28(4):583–91.
- 617 28. Kızılet H, Kasımoğlu C, Uysal H. Can the Rosa canina plant be used against alkylating agents
618 as a radical scavenger. Pol J Environ Stud. 2013;22(4):1263–7.
- 619 29. Uysal H, Kızılet H, Ayar A, Taheri A. The use of endemic Iranian plant, *Echium amoenum*,
620 against the ethyl methanesulfonate and the recovery of mutagenic effects. Toxicol Ind Health.
621 2015;31(1):44–51.

- 622 30. Arora A, Sairam RK, Srivastava GC. Oxidative stress and antioxidative system in plants. Curr
623 Sci. 2002;1227–38.
- 624 31. Dweck A. Purslane-the global panacea. 2001;
- 625 32. Lim YY, Quah EPL. Antioxidant properties of different cultivars of *Portulaca oleracea*. Food
626 Chem. 2007;103(3):734–40.
- 627 33. Byrne R, McAndrews JH. Pre-Columbian purslane (*Portulaca oleracea* L) in the New World.
628 Nature. 1975;253(5494):726–7.
- 629 34. Kumlay AM, Yıldız Ö, Yurt B, Zengin H. Some wild edible plants consumed traditionally in
630 Iğdır Türkiye. 1. 2010;
- 631 35. Simopoulos AP. Omega-3 fatty acids and antioxidants in edible wild plants. Biol Res.
632 2004;37(2):263–77.
- 633 36. Perry P, Wolff S. New Giemsa method for the differential staining of sister chromatids. Nature.
634 1974;251(5471):156–8.
- 635 37. Tucker JD, Auletta A, Cimino MC, Dearfield KL, Jacobson-Kram D, Tice RR, et al. Sister-
636 chromatid exchange: second report of the Gene-Tox Program. Mutation Research/Reviews in
637 Genetic Toxicology. 1993;297(2):101–80.
- 638 38. Fenech M. The in vitro micronucleus technique. Mutation Research/Fundamental and
639 Molecular Mechanisms of Mutagenesis. 2000;455(1–2):81–95.
- 640 39. Test No. 487: In Vitro Mammalian Cell Micronucleus Test. OECD Publishing; 2010.
- 641 40. Kirkland D, Kasper P, Müller L, Corvi R, Speit G. Recommended lists of genotoxic and non-
642 genotoxic chemicals for assessment of the performance of new or improved genotoxicity tests:
643 a follow-up to an ECVAM workshop. Mutation Research/Genetic Toxicology and
644 Environmental Mutagenesis. 2008;653(1–2):99–108.
- 645 41. Henderson NC, Rieder F, Wynn TA. Fibrosis: from mechanisms to medicines. Nature.
646 2020;587(7835):555–66.
- 647 42. Czepulkowski BH, Rooney DE. Human cytogenetics: A practical approach. IRL press; 1992.

- 648 43. Kirsch-Volders M, Elhajouji A, Cundari E, Van Hummelen P. The in vitro micronucleus test: a
649 multi-endpoint assay to detect simultaneously mitotic delay, apoptosis, chromosome breakage,
650 chromosome loss and non-disjunction. *Mutation Research/Genetic Toxicology and*
651 *Environmental Mutagenesis*. 1997;392(1–2):19–30.
- 652 44. Countryman PI, Heddle JA. The production of micronuclei from chromosome aberrations in
653 irradiated cultures of human lymphocytes. *Mutation Research/Fundamental and Molecular*
654 *Mechanisms of Mutagenesis*. 1976;41(2–3):321–31.
- 655 45. Kalyabina VP, Esimbekova EN, Kopylova K V, Kratasyuk VA. Pesticides: formulants,
656 distribution pathways and effects on human health—a review. *Toxicol Rep*. 2021;8:1179–92.
- 657 46. Kasimoglu C, Uysal H. Mutagenic biomonitoring of pirethroid insecticides in human
658 lymphocyte cultures: Use of micronuclei as biomarkers and recovery by *Rosa canina* extracts
659 of mutagenic effects. *Pharm Biol*. 2015;53(5):625–9.
- 660 47. Latt SA, Allen J, Bloom SE, Carrano A, Falke E, Kram D, et al. Sister-chromatid exchanges:
661 a report of the GENE-TOX program. *Mutation Research/Reviews in Genetic Toxicology*.
662 1981;87(1):17–62.
- 663 48. Loveday KS, Latt SA. Search for DNA interchange corresponding to sister chromatid
664 exchanges in Chinese hamster ovary cells. *Nucleic Acids Res*. 1978;5(11):4087–104.
- 665 49. Lakens D. Calculating and reporting effect sizes to facilitate cumulative science: a practical
666 primer for t-tests and ANOVAs. *Front Psychol*. 2013;4:863.
- 667 50. Chow SC, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research.
668 chapman and hall/CRC; 2017.
- 669 51. Cohen J. Statistical power analysis for the behavioral sciences. routledge; 2013.
- 670 52. Suzuki T, Hayashi M, Wang X, Yamamoto K, Ono T, Myhr BC, et al. A comparison of the
671 genotoxicity of ethylnitrosourea and ethyl methanesulfonate in lacZ transgenic mice (MutaTM
672 Mouse). *Mutation Research/Genetic Toxicology and Environmental Mutagenesis*.
673 1997;395(1):75–82.

- 674 53. Yang JL, Lee PC, Lin SR, Lin JG. Comparison of mutation spectra induced by N-ethyl-N-
675 nitrosourea in the hprt gene of Mer⁺ and Mer⁻ diploid human fibroblasts. *Carcinogenesis*.
676 1994;15(5):939–45.
- 677 54. Bronstein SM, Cochrane JE, Craft TR, Swenberg JA, Skopek TR. Toxicity, mutagenicity, and
678 mutational spectra of N-ethyl-N-nitrosourea in human cell lines with different DNA repair
679 phenotypes. *Cancer Res*. 1991;51(19):5188–97.
- 680 55. Anderson D, Yu TW, McGregor DB. Comet assay responses as indicators of carcinogen
681 exposure. *Mutagenesis*. 1998;13(6):539–55.
- 682 56. Siddique YH, Varshney H, Subhan I, Gaur K, Fatima J, Jyoti S. Evaluation of the toxic
683 potential of ethyl methanesulphonate (EMS) on *Hydra vulgaris*. *Toxicol Rep*. 2024;13:101839.
- 684 57. Amini M. Ethyl Methanesulfonate. 2014;
- 685 58. Müller L, Gocke E, Lavé T, Pfister T. Ethyl methanesulfonate toxicity in Viracept—a
686 comprehensive human risk assessment based on threshold data for genotoxicity. *Toxicol Lett*.
687 2009;190(3):317–29.
- 688 59. Štampar M, Žegura B. In vitro hepatic 3D cell models and their application in genetic
689 toxicology: A systematic review. *Mutation Research-Genetic Toxicology and Environmental*
690 *Mutagenesis*. 2024;503835.
- 691 60. Sundberg JP, Ichiki T. Genetically engineered mice handbook. CRC Press; 2016.
- 692 61. Basu AK, Essigmann JM. Site-specifically alkylated oligodeoxynucleotides: probes for
693 mutagenesis, DNA repair and the structural effects of DNA damage. *Mutation*
694 *Research/Fundamental and Molecular Mechanisms of Mutagenesis*. 1990;233(1–2):189–201.
- 695 62. de Bruijn E, Cuppen E, Feitsma H. Highly efficient ENU mutagenesis in zebrafish. *Zebrafish:*
696 *methods and protocols*. 2009;3–12.
- 697 63. Iyer VN, Szybalski W. Mitomycins and porfiromycin: chemical mechanism of activation and
698 cross-linking of DNA. *Science (1979)*. 1964;145(3627):55–8.

- 699 64. Danshiitsoodol N, de Pinho CA, Matoba Y, Kumagai T, Sugiyama M. The mitomycin C
700 (MMC)-binding protein from MMC-producing microorganisms protects from the lethal effect
701 of bleomycin: crystallographic analysis to elucidate the binding mode of the antibiotic to the
702 protein. *J Mol Biol.* 2006;360(2):398–408.
- 703 65. Sinitsky MY, Kutikhin AG, Tsepokina A V, Shishkova DK, Asanov MA, Yuzhalin AE, et al.
704 Mitomycin C induced genotoxic stress in endothelial cells is associated with differential
705 expression of proinflammatory cytokines. *Mutation Research/Genetic Toxicology and*
706 *Environmental Mutagenesis.* 2020;858:503252.
- 707 66. Yang Z, Liu C, Xiang L, Zheng Y. Phenolic alkaloids as a new class of antioxidants in *Portulaca*
708 *oleracea*. *Phytotherapy Research: An International Journal Devoted to Pharmacological and*
709 *Toxicological Evaluation of Natural Product Derivatives.* 2009;23(7):1032–5.
- 710 67. Rashed AN, Afifi FU, Disi AM. Simple evaluation of the wound healing activity of a crude
711 extract of *Portulaca oleracea* L.(growing in Jordan) in *Mus musculus* JVI-1. *J Ethnopharmacol.*
712 2003;88(2–3):131–6.
- 713 68. Surh YJ. Cancer chemoprevention with dietary phytochemicals. *Nat Rev Cancer.*
714 2003;3(10):768–80.
- 715 69. Ferguson LR, Philpott M. Nutrition and mutagenesis. *Annu Rev Nutr.* 2008;28(1):313–29.
- 716 70. Chen CJ, Wang WY, Wang XL, Dong LW, Yue YT, Xin HL, et al. Anti-hypoxic activity of the
717 ethanol extract from *Portulaca oleracea* in mice. *J Ethnopharmacol.* 2009;124(2):246–50.
- 718 71. Petropoulos SA, Fernandes Â, Dias MI, Vasilakoglou IB, Petrotos K, Barros L, et al.
719 Nutritional value, chemical composition and cytotoxic properties of common purslane
720 (*Portulaca oleracea* L.) in relation to harvesting stage and plant part. *Antioxidants.*
721 2019;8(8):293.
- 722 72. Oliveira I, Valentão P, Lopes R, Andrade PB, Bento A, Pereira JA. Phytochemical
723 characterization and radical scavenging activity of *Portulaca oleracea* L. leaves and stems.
724 *Microchemical Journal.* 2009;92(2):129–34.

- 725 73. Valko M, Leibfritz D, Moncol J, Cronin MTD, Mazur M, Telser J. Free radicals and
726 antioxidants in normal physiological functions and human disease. *Int J Biochem Cell Biol.*
727 2007;39(1):44–84.
- 728 74. Purkait MK, Duarah P, Das PP. Recovery of bioactives from food wastes. CRC Press; 2023.
- 729 75. Justice MJ, Noveroske JK, Weber JS, Zheng B, Bradley A. Mouse ENU mutagenesis. *Hum*
730 *Mol Genet.* 1999;8(10):1955–63.
- 731 76. Margison GP, Santibáñez-Koref MF. O6-alkylguanine-DNA alkyltransferase: Role in
732 carcinogenesis and chemotherapy. *Bioessays.* 2002;24(3):255–66.
- 733 77. Yang K, Greenberg MM. DNA–protein cross-link formation in nucleosome core particles
734 treated with methyl methanesulfonate. *Chem Res Toxicol.* 2019;32(10):2144–51.
- 735 78. Miao L, Zhou C, Zhang H, Cheong MS, Tan Y, Wang Y, et al. *Portulaca oleracea* L.(Purslane)
736 extract protects endothelial function by reducing endoplasmic reticulum stress and oxidative
737 stress through AMPK activation in diabetic obese mice. *Antioxidants.* 2023;12(12):2132.
- 738 79. Luo JH, Li J, Shen ZC, Lin XF, Chen AQ, Wang YF, et al. Advances in health-promoting
739 effects of natural polysaccharides: Regulation on Nrf2 antioxidant pathway. *Front Nutr.*
740 2023;10:1102146.
- 741 80. Chen WC, Wang SW, Li CW, Lin HR, Yang CS, Chu YC, et al. Comparison of various solvent
742 extracts and major bioactive components from *Portulaca oleracea* for antioxidant, anti-
743 tyrosinase, and anti- α -glucosidase activities. *Antioxidants.* 2022;11(2):398.
- 744 81. Carocho M, Morales P, Ferreira ICFR. Antioxidants: Reviewing the chemistry, food
745 applications, legislation and role as preservatives. *Trends Food Sci Technol.* 2018;71:107–20.
- 746 82. Aoudeh E, Şat İG, Binici Hİ. Chemical properties and antioxidant activity of different extracts
747 from purslane (*Portulaca oleracea* L.). *Tekirdağ Ziraat Fakültesi Dergisi.* 2024;21(1):81–93.
- 748